Cabaletta Bio to Join H.C. Wainwright BioConnect Conference at NASDAQ

PHILADELPHIA, May 13, 2024 — Cabaletta Bio (Nasdaq: CABA), a biotechnology firm in the clinical development stage, is pioneering the creation of tailored cell therapies aimed at curing autoimmune diseases. The company has announced that it will take part in a fireside discussion at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event is scheduled to take place at NASDAQ on Monday, May 20, 2024, at 9:30 a.m. ET in New York, NY.

The event will be accessible through a live webcast in the News and Events section of Cabaletta Bio’s website. For those unable to attend the live session, replays will remain available on the website for a duration of 30 days.

Cabaletta Bio Overview

Cabaletta Bio (Nasdaq: CABA) is dedicated to the innovation and clinical advancement of engineered T cell therapies, which hold the promise of being deep, durable, and potentially curative treatments for autoimmune disease patients. The company's proprietary CABA™ platform is built around two main strategies: the CARTA strategy, which focuses on chimeric antigen receptor T cells for autoimmunity, and the CAART strategy, which revolves around chimeric autoantibody receptor T cells.

Within the CARTA strategy, the lead product candidate is CABA-201, a fully human CD19-CAR T containing the 4-1BB co-stimulatory domain. This candidate is currently under evaluation in various RESET™ clinical trials targeting systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.

The CAART strategy features multiple candidates in clinical stages, including DSG3-CAART for the treatment of mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. Cabaletta Bio's expanding CABA™ platform aims to develop therapies that provide robust and long-lasting responses across a spectrum of autoimmune diseases.

Headquartered in Philadelphia, PA, Cabaletta Bio continues to push the boundaries of therapeutic possibilities for patients with difficult-to-treat autoimmune disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!